A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00051142

Recruitment Status : Completed

First Posted : January 7, 2003

Last Update Posted : August 5, 2008

Sponsor:

Information provided by:

Alcon Research

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.

Condition or disease	Intervention/treatment	Phase
Glaucoma, Open-Angle Ocular Hypertension	Drug: Travoprost Drug: Latanoprost	Phase 3

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma or Ocular Hypertension
Study Start Date :	February 2001
Actual Primary Completion Date :	June 2004
Actual Study Completion Date :	June 2004

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Early-onset glaucoma Hypertension

MedlinePlus related topics: Glaucoma

Drug Information available for: Latanoprost Travoprost

Genetic and Rare Diseases Information Center resources: Pigment-dispersion Syndrome

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Adult patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00051142

Locations

Layout table for location information

United States, Texas
Latin America
Fort Worth, Texas, United States

Sponsors and Collaborators

Alcon Research

Investigators

Layout table for investigator information

Principal Investigator:	Alcon Investigators	Alcon Research

More Information

Layout table for additonal information

ClinicalTrials.gov Identifier:	NCT00051142
Other Study ID Numbers:	C-01-36
First Posted:	January 7, 2003 Key Record Dates
Last Update Posted:	August 5, 2008
Last Verified:	August 2008

Keywords provided by Alcon Research:


Glaucoma POAG OAG OHT

Additional relevant MeSH terms:

Layout table for MeSH terms

Glaucoma Glaucoma, Open-Angle Ocular Hypertension Hypertension Vascular Diseases	Cardiovascular Diseases Eye Diseases Latanoprost Travoprost Antihypertensive Agents

To Top